Today: 7 February 2026
Subscribe
Browse Category

TSX:6146 News 9 December 2025 - 22 January 2026

Dow snaps back after Trump cools Greenland tariff threat; Asia rallies and gold slips from record

Dow snaps back after Trump cools Greenland tariff threat; Asia rallies and gold slips from record

Wall Street posted its strongest session in two months Wednesday after President Trump dropped tariff threats linked to Greenland, sending the S&P 500 up 1.16% and the Dow higher by 588 points. Asian markets followed, with South Korea’s Kospi briefly topping 5,000. Gold retreated from record highs as volatility eased. European shares and the euro also gained as investors awaited central bank decisions and key earnings.
22 January 2026
······
Tokyo Stock Market’s Biggest Gainers Today (December 9, 2025): Chip Makers, Industrials and Utilities Drive the Nikkei 225 Higher

Tokyo Stock Market’s Biggest Gainers Today (December 9, 2025): Chip Makers, Industrials and Utilities Drive the Nikkei 225 Higher

Tokyo – December 9, 2025 Market snapshot: Tokyo holds firm near record territory Japanese equities spent much of Tuesday in “wait and see” mode as global investors braced for a closely watched U.S. Federal Reserve meeting where a 25-basis‑point rate cut is now widely anticipated. Major houses including Nomura, J.P. Morgan and Morgan Stanley have shifted to expecting easing, even as they warn about a potentially divided Fed and a slower cutting cycle in 2026. Reuters+1 Despite that caution, Tokyo’s Nikkei 225 ended the day modestly higher, up about 0.2% near 50,700, according to official index data and exchange feeds.
9 December 2025
·········

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop